The Dish’s Weekly News Wrap Up – May 25, 2012

By on May 25, 2012

Just a reminder – please submit presentations and posters to be featured in The Cell Culture Dish’s Scientific Poster Hall.

“Canada Oks Osiris Drug; First Stem Cell Therapy,” Reuters

Osiris Therapeutics Inc. said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world.

If you like this story, please see our blog titled “Culture and Expansion of Stem Cells in Stirred Suspension Bioreactors Could Provide Key in Large Scale Manufacturing”

“Agilent Buys Dako for 2.2 Billion, Biggest Deal Ever,” Bloomberg

Agilent Technologies Inc. the maker of scientific-testing equipment, agreed to buy Dako, a Danish maker of cancer-diagnostics tools, for $2.2 billion in cash to expand its life-science business.

If you like this story, please see our blog titled “Corning Expands Life Science Business Through Recent Acquisitions”

 

“California Considers DNA Privacy Law,” Scientific American

California lawmakers are weighing a bill aimed at protecting their state’s citizens from surreptitious genetic testing but scientists are voicing their growing concerns that, if passed, such a law would have a costly and damaging effect on research.

If you like this story, please see our blog titled “Neonatal Stem Cells for Research and Clinical Applications”

 

“IPierian Zeroes in on Antibodies for Alzheimer’s, Neurodegeneration,” Xconomy

iPierian used to be known as a stem cell company, when stem cells were all the rage. But now it’s taking on a new identity as an antibody drug developer that happens to use stem cells as a tool for discovery.

If you like this story, please see our blog titled “Exciting Treatment Possibilities with Stem Cells – What is the Best Cell Culture Method”

 

“ReNeuron’s UK Stem Cell Trial Edges Towards Phase II,” PharmaTimes

UK-based stem-cell pioneer ReNeuron says it is on track to seek approval for a Phase II clinical trial of its ReN001 therapy in disabled stroke patients “during the course of next year”.

If you like this story, please see our stem cell blog titled “UC Davis Set to Launch California’s First Public Umbilical Cord Blood Bank”

 

“Report: Foreign Countries Want to Lure US Biotechs,” Mass High Tech

As the pharmaceutical industry lobbies for several biotech-friendly measures in Washington, an industry group is touting a study that says foreign countries are increasingly adopting biotech-friendly policies in an attempt to lure such companies away from the U.S.

If you like this story, please see our blog titled “CHO Cells the Top Expression System of Best Selling Biologic Drugs”

 

 

One Comment

  1. Pingback: The Cell Culture Dish » New Stem Cell Therapy May Prevent the Need for Hip Replacement Surgery

Leave a Reply

Your email address will not be published. Required fields are marked *